Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)
Gilead reported positive Phase 3 IDEAL results for Livdelzi (seladelpar) in PBC patients with milder ALP elevation (1-1.67x ULN) previously excluded from pivotal trials. At Week 52, 75.4% of Livdelzi-treated participants achieved the ALP normalization composite endpoint versus 16.1% on placebo, with response evident within one month and no new safety concerns.
Key figures
- Drug Name
- Livdelzi (seladelpar)
- Phase Of Trial
- Phase 3
- Enrolled
- 96
- Alp normalization month1
- 52.3% (Livdelzi) vs 6.5% (placebo)
- Alp normalization week52
- 75.4% (Livdelzi) vs 16.1% (placebo)
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.